CD274 and non-small cell lung carcinoma: Additionally, in 2020, this combination was approved for first-line treatment of adult patients with metastatic non-small-cell lung cancer (NSCLC), based on studies in which tumor PD-1 ligand (PD-L1) expression (≥ 1%) was used as a biomarker.